Ospolot tablets 200 mg


Consumers and health professionals are advised that Phebra Pty Ltd, in consultation with the TGA, has initiated a product defect alert for bottles of Ospolot (sulthiame) 200 mg tablets.

The affected batch numbers are:

  • 18003717 (expiry 05/21)
  • 28811 (expiry 11/22)

Ospolot (sulthiame) 200 mg tablets are used as an anticonvulsant for behavioural disorders associated with epilepsy; hyperkinetic behaviour; temporal lobe epilepsy; myoclonic seizures; grand mal attacks and Jacksonian seizures.

It has been identified that affected batches of Ospolot (sulthiame) 200 mg tablets have been supplied with child-resistant caps that may not function correctly. If this occurs, a child may be able to open a bottle and access the medicine, which could result in a potentially life-threatening risk.

/Public Release. This material comes from the originating organization and may be of a point-in-time nature, edited for clarity, style and length. View in full here.